Valuation: Myriad Genetics, Inc.

Market Cap 585M 511M 473M 434M 821M 56.33B 835M 5.64B 2.21B 27.51B 2.2B 2.15B 94.98B P/E 2026 *
-8.14x
P/E 2027 * -11.7x
Enterprise Value 585M 511M 473M 434M 821M 56.33B 835M 5.64B 2.21B 27.51B 2.2B 2.15B 94.98B EV / Sales 2026 *
0.68x
EV / Sales 2027 * 0.64x
Free-Float
96.24%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week+1.48%
Current month+8.41%
1 month+45.65%
3 months+23.80%
6 months+4.56%
Current year+0.65%
1 week 5.67
Extreme 5.67
6.43
1 month 4.39
Extreme 4.39
6.43
Current year 3.53
Extreme 3.53
7.15
1 year 3.53
Extreme 3.53
8.59
3 years 3.53
Extreme 3.53
29.3
5 years 3.53
Extreme 3.53
36.95
10 years 3.53
Extreme 3.53
50.44
Manager TitleAgeSince
Chief Executive Officer 54 30/04/2025
Director of Finance/CFO 43 16/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman 67 23/03/2020
Director/Board Member 71 10/06/2010
Director/Board Member 66 25/09/2019
Date Insider Type Main position Quantity % Market Cap.
23/6/26 Other

Director

0 0%
11/6/26 Free

Executive/Senior Manager

5,000 0.0053%
11/6/26 Free

Chief Executive Officer

3,542 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%+1.48%+22.33%-72.49% 585M
-4.88%-5.53%+224.20%+304.49% 20.55B
+0.83%+5.01%-38.04%-21.45% 9.81B
+0.75%-0.83%+41.25%+22.09% 6.84B
-2.78%+3.20%+259.58%-23.44% 5.65B
+2.44%+7.12%-16.40%-28.79% 5.22B
-5.61%-7.78%-47.52% - 4.66B
+0.06%+1.45%-22.59%-24.27% 4.23B
+7.48%+23.37%+86.53%+108.39% 4.46B
+2.00%+8.24%-12.85%-39.00% 2.79B
Average -0.16%+2.56%+49.65%+25.06% 6.48B
Weighted average by Cap. -1.20%+0.27%+91.72%+102.19%

Financials

2026 *2027 *
Net sales 864M 755M 698M 641M 1.21B 83.21B 1.23B 8.33B 3.27B 40.64B 3.24B 3.17B 140B 916M 801M 740M 679M 1.29B 88.25B 1.31B 8.83B 3.47B 43.09B 3.44B 3.36B 149B
Net income -71.48M -62.48M -57.78M -53.02M -100M -6.89B -102M -689M -271M -3.36B -268M -263M -11.61B -50.98M -44.56M -41.21M -37.81M -71.57M -4.91B -72.81M -491M -193M -2.4B -191M -187M -8.28B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
16/07/26 USD 6.190 -1.90% 965,983
15/07/26 USD 6.310 +4.47% 1,100,550
14/07/26 USD 6.040 +3.07% 896,466
13/07/26 USD 5.860 +0.51% 811,599
10/07/26 USD 5.830 -4.43% 856,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
6.190USD
Average target price
6.250USD
Spread / Average Target
+0.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock